CN104256610B - A kind of health composition of auxiliary antilipemic and soft capsule - Google Patents
A kind of health composition of auxiliary antilipemic and soft capsule Download PDFInfo
- Publication number
- CN104256610B CN104256610B CN201410536072.8A CN201410536072A CN104256610B CN 104256610 B CN104256610 B CN 104256610B CN 201410536072 A CN201410536072 A CN 201410536072A CN 104256610 B CN104256610 B CN 104256610B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- oil
- health composition
- evening primrose
- soft capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 230000036541 health Effects 0.000 title claims abstract description 40
- 239000007901 soft capsule Substances 0.000 title claims abstract description 29
- 230000002402 anti-lipaemic effect Effects 0.000 title claims abstract description 18
- 229940106134 krill oil Drugs 0.000 claims abstract description 44
- 150000002148 esters Chemical class 0.000 claims abstract description 32
- 239000002775 capsule Substances 0.000 claims abstract description 18
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 18
- 239000008158 vegetable oil Substances 0.000 claims abstract description 18
- 235000008524 evening primrose extract Nutrition 0.000 claims description 34
- 229940089020 evening primrose oil Drugs 0.000 claims description 34
- 239000010475 evening primrose oil Substances 0.000 claims description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- 239000001335 perilla frutescens leaf extract Substances 0.000 claims description 17
- 235000011187 glycerol Nutrition 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 12
- 108010010803 Gelatin Proteins 0.000 claims description 12
- 239000008273 gelatin Substances 0.000 claims description 12
- 229920000159 gelatin Polymers 0.000 claims description 12
- 235000019322 gelatine Nutrition 0.000 claims description 12
- 235000011852 gelatine desserts Nutrition 0.000 claims description 12
- 239000008213 purified water Substances 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 44
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 30
- 235000012000 cholesterol Nutrition 0.000 abstract description 14
- 239000002131 composite material Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000002253 acid Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 5
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 5
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 4
- -1 cupreol ester Chemical class 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 4
- 235000004626 essential fatty acids Nutrition 0.000 description 4
- 235000021323 fish oil Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000239366 Euphausiacea Species 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 241000219925 Oenothera Species 0.000 description 2
- 235000004496 Oenothera biennis Nutrition 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- 229960002733 gamolenic acid Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 241000229722 Perilla <angiosperm> Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
- A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a kind of health composition of auxiliary antilipemic, comprises krill oil 2 ~ 8 weight portion, vegetable oil 2 ~ 8 weight portion, phytosterin ester 1.5 ~ 8 weight portion.The present invention also discloses a kind of soft capsule of the auxiliary antilipemic be made up as Contents Fill to capsule shells of aforementioned health composition.The present invention due to adopt krill oil and vegetable oil and phytosterin ester composite with appropriate ratio, this three's Synergistic, thus reach and can reduce cholesterol, can reduce again the object of triglycerides.
Description
Technical field
The present invention relates to the technical field of blood fat reducing health products, a kind of with the health composition of auxiliary antilipemic and soft capsule specifically.
Background technology
Blood fat refers to that cholesterol, triglycerides (triglyceide, TG) and lipoid in blood plasma is as the general name of phosphatide etc.With clinical closely-related blood fat mainly cholesterol and triglycerides, other also have free fatty and phosphatide etc.In human body, cholesterol mainly exists with CHF and cholesteryl ester form.Triglycerides is that three hydroxyls in glycerol molecule are formed by fatty acid esterification.Cholesterol in blood circulation and triglycerides must combine with special protein and apolipoprotein (apolipoprotein, ap) and form lipoprotein, just can be transported to tissue and carry out metabolism.
The lipid-regulation medicine Gong selecting clinically at present is mainly divided into five classes: (1) Statins; (2) the special class of shellfish; (3) nicotinic acid class; (4) resinae; (5) cholesterol absorption inhibitor.But individuality has very large individual difference to curative effect of medication and side effect, side effect is many, and generally needs long-term taking.So only after diet and Exercise therapy for treatment of knee joint, just try out when still effectively can not reduce blood fat.
Existing tune fat prod on the market, triglycerides or cholesterol one wherein can only be reduced, can not realize all sidedly adjusting fat, as can be seen here, how a kind of health product is provided, can either reduce the triglycerides of user, can reduce cholesterol again, this is the current technical issues that need to address in this area.
Summary of the invention
In view of this, the object of this invention is to provide a kind of health composition of auxiliary antilipemic, after human body is taken, can triglycerides be reduced, can cholesterol be reduced again.Based on this, the present invention also provides a kind of soft capsule, is made up as Contents Fill of aforementioned health composition to capsule shells.
For solving the problems of the technologies described above, technical scheme of the present invention is:
A health composition for auxiliary antilipemic, comprises krill oil 2 ~ 8 weight portion, vegetable oil 2 ~ 8 weight portion, phytosterin ester 1.5 ~ 8 weight portion.
Preferably, described vegetable oil is described vegetable oil is evening primrose oil and/or Purple Perilla Seed Oil.
Preferably, described vegetable oil is evening primrose oil, and the health composition of auxiliary antilipemic is made up of krill oil 2 ~ 3 weight portion, evening primrose oil 2.5 ~ 3.5 weight portion, phytosterin ester 2 ~ 2.5 weight portion.
Preferably, described vegetable oil is evening primrose oil, and the health composition of auxiliary antilipemic is made up of krill oil 2.5 weight portion, evening primrose oil 3.5 weight portion, phytosterin ester 2 weight portion.
Preferably, described vegetable oil is evening primrose oil Purple Perilla Seed Oil, and the health composition of auxiliary antilipemic is made up of krill oil 2 ~ 3 weight portion, Purple Perilla Seed Oil 2.5 ~ 3.5 weight portion, phytosterin ester 2 ~ 2.5 weight portion.
Preferably, described vegetable oil is the mixture that evening primrose oil and Purple Perilla Seed Oil mix with the weight ratio of 1:1 ~ 3:1.
Preferably, the health composition of auxiliary antilipemic is made up of krill oil 2.5 weight portion, evening primrose oil 3.5 weight portion, Purple Perilla Seed Oil 3.5 weight portion, phytosterin ester 2 weight portion.
A soft capsule for auxiliary antilipemic, is made up as in Contents Fill to capsule shells of aforesaid health composition.
Preferably, described capsule shells is made up of gelatin 200-500 weight portion, glycerine 40-90 weight portion, D-sorbite 40-80 weight portion, purified water 250 ~ 350 weight portion.
Preferably, described capsule shells is made up of gelatin 250 ~ 450 weight portion, glycerine 50 ~ 80 weight portion, D-sorbite 50 ~ 70 weight portion, purified water 270 ~ 320 weight portion.
Preferably, described capsule shells is made up of gelatin 356 weight portion, glycerine 78 weight portion, D-sorbite 63 weight portion, purified water 289 weight portion.
Compared with prior art, the present invention due to adopt krill oil and vegetable oil and phytosterin ester composite with appropriate ratio, this three's Synergistic, thus reach and can reduce cholesterol, can reduce again the object of triglycerides.
Further, due to krill oil comparatively thickness, easily bond with capsule wall and cause capsules break when making soft capsule, the problem of generation leakage of oil, krill oil is equipped with the vegetable oil of proper ratio by the present invention, phytosterin ester dilutes, and solves the problem making soft capsule leakage of oil.
Detailed description of the invention
Of the present inventionly to be contemplated that, a kind of health composition of auxiliary antilipemic to be provided, to comprise krill oil 2 ~ 8 weight portion, evening primrose oil 2 ~ 8 weight portion, phytosterin ester 1.5 ~ 8 weight portion.
Krill oil is the grease extracted from krill.Krill is the biology the highest containing protein that people have been found that today, protein content reaches more than 50 percent, but also containing the very abundant necessary amino acid of tissue and vitamin A, krill oil contains Omega-3 essential fatty acid eicosapentaenoic acid (EPA) and DHA (DHA).Omega-3 essential fatty acid has a lot of sanatory benefit, comprises cardiovascular, neural, bone and joint, eyesight, skin care etc.In cardiovascular, cholesterol, prevention cerebral hemorrhage, cerebral thrombus can be reduced, blood viscosity can be reduced, stimulate circulation, preventing hypertension, can brain tonic and intelligence development, active thinking, prevention senile dementia.
Evening primrose oil is the grease extract from the seed of evening primrose, and the main composition of evening primrose oil is the gamma-Linolenic acid being described as " 21st century functional medicinal food leading role ", and it is otherwise known as vitaminF, is described as flowers of life; " royal imperial medicine " or " king's medicine " is referred to as in Europe.
Evening primrose seed contains abundant essential fatty acid " γ-linolenic acid ", structurally analyze is belong to the special necessary aliphatic acid of ω-6 series, be different from ω-6 linolenic acid contained in general vegetable oil, soybean oil, sunflower oil, therefore play many important roles in vivo.But human body can not manufacture GLA voluntarily, therefore must absorb from food, evening primrose oil is containing abundant GLA (soybean oil, sunflower oil be not containing GLA).Evening primrose oil is the same with deep sea fish oil, all belong to extremely polynary undersaturated essential fatty acid, the endogenous factor of inflammatory that peanut oil tetraenoic acid produces in vivo can be replaced in the process of metabolism in vivo, therefore, except anti-inflammatory effect, evening primrose oil also has the effect reducing Coagulation test, antithrombotic.
Purple Perilla Seed Oil obtains from the seed of the maturation of Labiatae medicinal plant purple perilla (Perillafrutesccns), it is a kind of natural oil of high degree of unsaturation, contained Main Ingredients and Appearance is alpha-linolenic acid, content, up to 50%-70%, is that in all crude vegetals found at present, this content of fatty acid is the highest.Purple Perilla Seed Oil is a kind of natural oil of high degree of unsaturation, to reduce cholesterol, reduce blood fat, atherosclerosis, reduction cerebral thrombus and angiocardiopathy have dauer effect.Alpha-linolenic acid can change into 20 carbon 5 olefin(e) acids (EPA) and 22 carbon 6 olefin(e) acids (DHA) after taking in human body under the effect of enzyme in human body, it is exactly the Main Ingredients and Appearance of deep sea fish oil, therefore plant deep sea fish oil is again, be more preferably it not containing cholesterol than deep sea fish oil, EPA and DHA has reducing blood lipid and improves the effect of memory.
Phytosterin ester is generally obtained by esterification or transesterification by phytosterol and aliphatic acid.Because the sterol and fatty acid species that may be used for manufacture phytosterin ester are all more, therefore can obtain the phytosterin ester of multiple different physicochemical property, three kinds of major phytosterols esters are cupreol ester, stigmasterol ester, campesterol ester.Sterol ester can change into sterol and aliphatic acid in human body, so its physiological function comprises the physiological function that phytosterol and aliphatic acid two parts have, there is the attenuating total plasma cholesterol equal with free phytosterol and the effect of LDL-C, in some aspects even better effects if.
In order to make those skilled in the art understand technical scheme of the present invention better, below by specific embodiment, the present invention is described in further detail.
Embodiment one
Health composition in the present embodiment, is made up of krill oil 2.5 weight portion, evening primrose oil 3.5 weight portion, phytosterin ester 2 weight portion.
The soft capsule that the health composition of the present embodiment is made comprises:
Content: krill oil 250g, evening primrose oil 350g, phytosterin ester 200g;
Capsule shells: gelatin 356g, glycerine 78g, D-sorbite 63g, purified water 289g.
Embodiment two
Health composition in the present embodiment, is made up of krill oil 2 weight portion, evening primrose oil 3.5 weight portion, phytosterin ester 2.5 weight portion.
The soft capsule that the health composition of the present embodiment is made comprises:
Content: krill oil 200g, evening primrose oil 350g, phytosterin ester 250g;
Capsule shells: gelatin 420g, glycerine 66g, D-sorbite 54g, purified water 292g.
Embodiment three
Health composition in the present embodiment, is made up of krill oil 3 weight portion, evening primrose oil 2.5 weight portion, phytosterin ester 2.5 weight portion.
The soft capsule that the health composition of the present embodiment is made comprises:
Content: krill oil 300g, evening primrose oil 250g, phytosterin ester 250g;
Capsule shells: gelatin 450g, glycerine 86g, D-sorbite 59g, purified water 300g.
Embodiment four
Health composition in the present embodiment, is made up of krill oil 2 weight portion, Purple Perilla Seed Oil 8 weight portion, phytosterin ester 2 weight portion.
The soft capsule that the health composition of the present embodiment is made comprises:
Content: krill oil 200g, evening primrose oil 800g, phytosterin ester 200g;
Capsule shells: gelatin 409g, glycerine 52g, D-sorbite 61g, purified water 295g.
Embodiment five
Health composition in the present embodiment, is made up of krill oil 8 weight portion, evening primrose oil 3 weight portion, phytosterin ester 5 weight portion.
The soft capsule that the health composition of the present embodiment is made comprises:
Content: krill oil 800g, evening primrose oil 300g, phytosterin ester 500g;
Capsule shells: gelatin 200g, glycerine 55g, D-sorbite 65g, purified water 280g.
Embodiment six
Health composition in the present embodiment, is made up of krill oil 250 weight portion, Purple Perilla Seed Oil 350 weight portion, evening primrose oil 350 weight portion, phytosterin ester 200 weight portion.
The soft capsule that the health composition of the present embodiment is made comprises:
Content: krill oil 250g, evening primrose oil 350g, Purple Perilla Seed Oil 350g, phytosterin ester 200g;
Capsule shells: gelatin 356g, glycerine 78g, D-sorbite 63g, purified water 289g.
Below by way of testing the security of health composition of the present invention and both effectivenessly verifying:
One, health composition human body of the present invention and animal body safety testing:
1, animal used as test
Secondary Wistar male rat 90, body weight 160-200g.
2, experimental technique
Feed rat after 5 days with basal feed, fasting, weighs, and gets tail blood, enzymatic assays serum total cholesterol (TC), triglycerides (TG).According to TC level, animal is divided into 9 groups, is respectively:
From formally testing beginning, except blank group gives except basal feed, all the other each dosage groups all give high lipid food.Each treated animal is used high lipid food (proportioning: basal feed 93.3%, cholesterol 1.5%, lard 5%, cholate 0.2%) instead and is fed.Give animal subject in gavage mode, blank group and model control group give distilled water in gavage mode, and oily control group gives common ready-mixed oil in gavage mode, and all the other each group gives each tested material in gavage mode.In 28 days observation cycles, to get before blood fasting 12 hours at every turn, every day gavage once, weigh when the 14th, 28 day, get the every blood lipids index of tail hematometry.
3, experimental result
(1) krill oil soft capsule is on the impact of rat body weight
As seen from Table 1, model group compares with blank group, before experiment, body weight (initial weight) is consistent, wherein, after the D28 week of modeling, compared with blank group, model control group body weight is that conspicuousness increases, and difference has pole conspicuousness statistical significance (p<0.01).At the end of experiment, test group group body weight compares with model control group downward trend, but no significant difference (p>0.05).
Table 1 krill oil soft capsule is on the impact (n=10, x ± s) of rat body weight
| Group | Initial weight | D14 | D28 |
| Blank group | 239.3±14.8 | 347.7±14.2 | 436.4±13.8 |
| Model control group | 240.8±25.1 | 358.8±20.6 | 474.2±10.3** |
| Common ready-mixed oil control group | 240.3±14.4 | 367.1±26.0 | 473.8±9.8 |
| First control group | 239.6±20.2 | 362.1±28.8 | 466.2±11.5 |
| Second control group | 238.2±10.3 | 357.7±20.3 | 464.7±9.82 |
| 3rd control group | 239.7±10.6 | 358.7±14.2 | 465.9±9.78 |
| First test group | 240.7±12.6 | 348.8±15.2 | 463.1±15.4 |
| Second test group | 239.7±15.6 | 347.6±10.6 | 460.9±16.22 |
| 3rd test group | 240.7±12.6 | 347.8±14.6 | 459.8±17.6 |
Each experimental group rat body weight and blank group are compared with oily control group without significant difference (p > 0.05).
(2) krill oil soft capsule affects Serum TC concentration
Measure when experiment the 28th day, the first ~ tri-rats in test groups serum TC concentration is remarkable in model control group and oily control group (p < 0.01) respectively.
(3) krill oil soft capsule affects rat blood serum TG concentration
Within 14th day, measure in experiment, the first ~ tri-rats in test groups serum TG is significantly lower than oily control group; Within 28th day, measure in experiment, the first ~ tri-rats in test groups serum TG is remarkable in model control group and oily control group (p < 0.01) respectively.
(4) krill oil soft capsule is on the impact of Serum Lipids in Experimental HypercholesterolemicRats
From following table 2, with the krill oil soft gel products of the first ~ tri-test group oil gavage, when the 28th day, compared with model control group, serum TC decline percentage is respectively 9.5%, 10%, 11.3%, and compared with oily control group, serum TC decline percentage is respectively 19.6%, 20%, 21%.With the krill oil soft gel products of the first ~ tri-test group oil gavage, when the 28th day, compared with model control group, serum TG decline percentage is respectively 13.6%, 15.0%, 25.8%, compared with oily control group, serum TG decline percentage is respectively 24.4%, 25.6%, 35.1%.
Table 2 krill oil soft capsule is on the impact (n=10, x ± s) of rat TC, TG
| Group | TC(mmol/L) | TG(mmol/L) |
| Blank group | 1.68±0.25 | 0.79±0.04 |
| Model control group | 2.40±0.17 | 1.47±0.11 |
| Common ready-mixed oil control group | 2.70±0.2 | 1.68±0.05 |
| First control group | 2.28±0.2 | 1.45±0.45 |
| Second control group | 2.34±0.12 | 1.55±0.22 |
| 3rd control group | 2.33±0.09 | 1.57±0.26 |
| First test group | 2.17±0.14 | 1.27±0.05 |
| Second test group | 2.16±0.12 | 1.25±0.08 |
| 3rd test group | 2.13±0.13 | 1.09±0.10 |
4, conclusion
Experimental result shows: give the first ~ tri-test group krill oil soft capsule, can make to feed raise high lipid food rat serum total cholesterol (TC) concentration significantly lower than model control group and oily control group; Serum triglyceride (TG) concentration is significantly lower than model control group and oily control group.
Two, health composition of the present invention is carried out human feeding trial, result is as follows:
1, experimenter selects: select non-simple hyperlipemia of being in hospital, voluntary participation, all keep former diet and habits and customs constant, the state of an illness is more stable, twice Diagnostic Value of Fasting Serum T-CHOL (TC) >=5.2mmol/L or post-prandial serum triglycerides (TG) >=1.65mmol/L in half a year.
2, packet design and test-meal method: by 180 experimenters, be divided into three groups at random by blood lipid level, wherein test-meal component test-meal group 1, test-meal group 2, each 60 examples.Three groups of ages, sex and eating habit suitable, former habits and customs and eating habit constant, test-meal group 1 adds food krill oil soft capsule (evening primrose oil), test-meal group 2 adds food krill oil soft capsule (Purple Perilla Seed Oil), every day 2 times, each 2, edible 30 days continuously, control group was blank.Each group adopts own control design, for contrasting between group between three groups.
Test-meal group 1 (containing evening primrose oil): krill oil 200g, evening primrose oil 350g, phytosterin ester 250g
Test-meal group 2 (containing Purple Perilla Seed Oil): krill oil 200g, Purple Perilla Seed Oil 350g, phytosterin ester 250g
3, instrument and reagent: F-820 type blood counting instrument, MIDIRON urinates ten analyzers (Germany produces), and Olympus automatic clinical chemistry analyzer AU600 (Japan produces), biochemical reagents box is all provided by Zhong Sheng company.
4, observation index:
1), general status is observed: observe general status and comprise spirit, sleep, diet, stool and urine, blood pressure etc.
2), blood, urine, feces routine inspection
3), Liver and kidney function inspection
4), Abdominal B type ultrasonography, electrocardiogram, X-ray chest-fluoroscopy have an X-rayed
5), both effectiveness observation: serum total cholesterol (TC) level reduces percentage well, triglycerides (TG) level and reduction percentage, high-density protein cholesterol (HDL-C) level and ascensional range.
6), effect criterion:
Effective: TC reduces > 10%, TG and reduces > 15%, HDL-C > 0.104mmol/L.
5, result judges:
Human feeding trial result judges: 1., serum total cholesterol, triglycerides binomial index be positive, and HDL-C, not significantly lower than control group, can judge that this given the test agent has auxiliary lipid-lowering function effect; 2. an index positive in serum total cholesterol, triglycerides binomial index, HDL-C, not significantly lower than control group, can judge that this given the test agent has auxiliary reduction serum total cholesterol or the effect of auxiliary reduction triglycerides.
6, result:
1), physical data: observe 180 examples altogether, wherein effectively case 160 is routine.Test-meal group 1 male sex 27 example, women 25 example, minimum 33 years old of age, the oldest 62 years old, average 50 years old; Test-meal group 2 male sex 27 example, women 26 example, minimum 35 years old of age, the oldest 61 years old, average 51 years old; The control group male sex 28 example, women 25 example, minimum 34 years old of age, maximum 63 years old, average 51 years old.
2), before two groups of test-meals, status of blood lipid and ordinary circumstance compare:
Before table 3 test-meal, status of blood lipid and ordinary circumstance compare (X ± SD)
Table 4, krill oil soft capsule are on the impact of T-CHOL
Self anterior-posterior horizontal compares: * P < 0.05, * * P<0.01; Between test-meal group with control group group, level compares: ##P < 0.01
From table 4, before and after test-meal test-meal group self and compared with control group total cholesterol level obviously reduce.
Table 5, krill oil soft capsule are on the impact (mmol/L, X ± SD) of triglycerides (TG)
Self anterior-posterior horizontal compares: * P < 0.05, * * P<0.01; Between test-meal group with control group group, level compares: ##P < 0.01.
From table 5, before and after test-meal test-meal group self and compared with control group triglyceride levels obviously reduce.
Below be only the preferred embodiment of the present invention, it should be pointed out that above-mentioned preferred embodiment should not be considered as limitation of the present invention, protection scope of the present invention should be as the criterion with claim limited range.For those skilled in the art, without departing from the spirit and scope of the present invention, can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (9)
1. a health composition for auxiliary antilipemic, is characterized in that, comprises krill oil 2 ~ 8 weight portion, vegetable oil 2 ~ 8 weight portion, phytosterin ester 1.5 ~ 8 weight portion;
Described vegetable oil is evening primrose oil and/or Purple Perilla Seed Oil.
2. health composition as claimed in claim 1, it is characterized in that, described vegetable oil is evening primrose oil, and described health composition is made up of krill oil 2 ~ 3 weight portion, evening primrose oil 2.5 ~ 3.5 weight portion, phytosterin ester 2 ~ 2.5 weight portion.
3. health composition as claimed in claim 1, it is characterized in that, described vegetable oil is evening primrose oil, and described health composition is made up of krill oil 2.5 weight portion, evening primrose oil 3.5 weight portion, phytosterin ester 2 weight portion.
4. health composition as claimed in claim 1, it is characterized in that, described vegetable oil is Purple Perilla Seed Oil, and described health composition is made up of krill oil 2 ~ 3 weight portion, Purple Perilla Seed Oil 2.5 ~ 3.5 weight portion, phytosterin ester 2 ~ 2.5 weight portion.
5. health composition as claimed in claim 1, it is characterized in that, described vegetable oil is the mixture that evening primrose oil and Purple Perilla Seed Oil mix with the weight ratio of 1:1 ~ 3:1.
6. a soft capsule for auxiliary antilipemic, is characterized in that, is made up as in Contents Fill to capsule shells of the health composition described in any one of claim 1-5.
7. the soft capsule of auxiliary antilipemic as claimed in claim 6, it is characterized in that, described capsule shells is made up of gelatin 200-500 weight portion, glycerine 40-90 weight portion, D-sorbite 40-80 weight portion, purified water 250 ~ 350 weight portion.
8. the soft capsule of auxiliary antilipemic as claimed in claim 6, it is characterized in that, described capsule shells is made up of gelatin 250 ~ 450 weight portion, glycerine 50 ~ 80 weight portion, D-sorbite 50 ~ 70 weight portion, purified water 270 ~ 320 weight portion.
9. the soft capsule of auxiliary antilipemic as claimed in claim 6, it is characterized in that, described capsule shells is made up of gelatin 356 weight portion, glycerine 78 weight portion, D-sorbite 63 weight portion, purified water 289 weight portion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410536072.8A CN104256610B (en) | 2014-10-11 | 2014-10-11 | A kind of health composition of auxiliary antilipemic and soft capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410536072.8A CN104256610B (en) | 2014-10-11 | 2014-10-11 | A kind of health composition of auxiliary antilipemic and soft capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104256610A CN104256610A (en) | 2015-01-07 |
| CN104256610B true CN104256610B (en) | 2016-04-06 |
Family
ID=52148295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410536072.8A Active CN104256610B (en) | 2014-10-11 | 2014-10-11 | A kind of health composition of auxiliary antilipemic and soft capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104256610B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104522649B (en) * | 2014-12-18 | 2016-08-17 | 润科生物工程（福建）有限公司 | A kind of DHA algal oil soft capsule containing Oleum Perillae and preparation method thereof |
| CN105613791A (en) * | 2016-01-26 | 2016-06-01 | 许勇男 | Health-care vegetable oil and preparation method thereof |
| CN106418542A (en) * | 2016-09-26 | 2017-02-22 | 南京中生生物科技有限公司 | Health-care product having function of regulating blood lipids and preparation method thereof |
| CN107987948A (en) * | 2017-06-25 | 2018-05-04 | 青岛康境海洋生物科技有限公司 | A kind of krill oil formulation for adjusting blood fat |
| CN108124981A (en) * | 2018-01-30 | 2018-06-08 | 湖南嘉耘油脂有限公司 | The edible oil and preparation method of a kind of reinforcing phytosterin ester and gamma-Linolenic acid |
| CN109349673B (en) * | 2018-10-22 | 2021-10-08 | 辽渔南极磷虾科技发展有限公司 | Euphausia superba oil soft capsule shell, soft capsule and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103141845B (en) * | 2013-03-22 | 2014-11-05 | 山东三星玉米产业科技有限公司 | Soft phytosterol capsule and method for preparing same |
| CN103385493A (en) * | 2013-07-18 | 2013-11-13 | 青岛银龄美海洋生物科技有限公司 | Healthy food using Antarctic krill oil as main ingredient |
| CN104000244B (en) * | 2014-06-16 | 2015-09-23 | 青岛银色世纪健康产业集团有限公司 | A kind of krill fat capsule and preparation method thereof |
-
2014
- 2014-10-11 CN CN201410536072.8A patent/CN104256610B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104256610A (en) | 2015-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104256610B (en) | A kind of health composition of auxiliary antilipemic and soft capsule | |
| US11135230B2 (en) | Lipid compositions with high DHA content | |
| Johnson et al. | Effect of dietary linoleic acid on markers of inflammation in healthy persons: a systematic review of randomized controlled trials | |
| Daksha et al. | Estimation of sterols content in edible oil and ghee samples | |
| dos Santos et al. | Multivariate analysis of the mineral content of raw and cooked okra (Abelmoschus esculentus L.) | |
| CN101720822A (en) | Nutritional blend oil with balanced fatty acid component and active component for middle and old aged | |
| CN105394182A (en) | Nutritional steamed stuffed bun with blood sugar reducing and heart and cerebral vessel health promoting efficacy | |
| CN103190619A (en) | Fish oil and linseed oil soft capsules and preparation method thereof | |
| CN101632402A (en) | High-grade nutrient health care edible oil | |
| CN108835262A (en) | A kind of modulation milk powder and preparation method thereof improving memory | |
| BRPI0407338B1 (en) | dietary nutrient or food supplement comprising an edible composition as well as an orally administrable pharmaceutical composition and uses thereof | |
| Subermaniam et al. | Virgin Coconut Oil (VCO) decreases the level of malondialdehyde (MDA) in the cardiac tissue of experimental Sprague-Dawley rats fed with heated palm oil | |
| CN103141845B (en) | Soft phytosterol capsule and method for preparing same | |
| CN107260801A (en) | Astaxanthin purple perilla soft capsule and preparation method | |
| CN101530138A (en) | Medium-long chain health care prandial oil | |
| CN105616557A (en) | Self-emulsifying soft capsule with peony seed oil and application of self-emulsifying soft capsule to preparing blood fat reducing healthcare products or medicines | |
| JPS61118318A (en) | Composition having improving action on serum lipid | |
| CN103766507A (en) | Edible oil with health-care function | |
| JPS6336744A (en) | Edible oil and fat composition effective in preventing allergy, thrombosis and hypertension | |
| Lee | Essent ial Fat ty Acids | |
| CN102802428B (en) | Fluid composition, comprises the preparation of described fluid composition, and reduces visceral fat accumulation, improves glucose tolerance and prevention or treatment obesity-related disease and the application of disease | |
| CN105707568A (en) | Alpha-linolenic acid soft capsule with function of auxiliarily lowering blood lipids and preparation method thereof | |
| CN1141934C (en) | Health-care oil for regulating blood fat | |
| Akl | Oilseeds Dietary Fiber and Their Health Benefits | |
| CN108703373A (en) | A kind of seven color nutrients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |